FIBROGEN INC - COMMON

FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease

17 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform

16 Jun 2021 07:00:01 By Nasdaq GlobeNewswire

FibroGen to Present at Upcoming Investor Conferences

27 May 2021 06:00:00 By Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2021 Financial Results

10 May 2021 15:01:00 By Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2021 Financial Results

03 May 2021 06:00:00 By Nasdaq GlobeNewswire

FibroGen to Present at Upcoming Investor Conference

28 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

15 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

12 Apr 2021 06:00:01 By Nasdaq GlobeNewswire

FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021

06 Apr 2021 18:50:31 By Nasdaq GlobeNewswire

FibroGen Provides Additional Information on Roxadustat

06 Apr 2021 15:01:00 By Nasdaq GlobeNewswire

FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

16 Mar 2021 06:00:00 By Nasdaq GlobeNewswire

FibroGen Provides Regulatory Update on Roxadustat

01 Mar 2021 15:01:00 By Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results

01 Mar 2021 15:01:00 By Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results

18 Feb 2021 06:00:01 By Nasdaq GlobeNewswire

FibroGen to Present at Upcoming Investor Conferences

12 Feb 2021 06:00:00 By Nasdaq GlobeNewswire